We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-2.59%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
-$184M
(-7.4%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-4.44%
Top 10 Holdings %
Top 10 Hldgs %
48.71%
Holding
92
New
20
Increased
22
Reduced
16
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$139M |
| 2 |
Cencora
COR
|
+$76M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$69.6M |
| 4 |
Centene
CNC
|
+$65.7M |
| 5 |
McKesson
MCK
|
+$56.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$106M |
| 2 |
Humana
HUM
|
+$106M |
| 3 |
Danaher
DHR
|
+$103M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$92.3M |
| 5 |
CVS Health
CVS
|
+$91.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.69% |
| 2 | Consumer Discretionary | 4.5% |
| 3 | Real Estate | 3.92% |
| 4 | Financials | 1.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Becton Dickinson
BDX
$48.8B
| $34.5M | 1.49% |
+144,054
| New | +$35.3M |
|
27
Align Technology
ALGN
$12.1B
| $31.1M | 1.34% |
46,730
-72,050
| -61% | -$48.9M |
|
28
Vertex Pharmaceuticals
VRTX
$123B
| $23.6M | 1.02% |
130,290
+12,330
| +10% | +$2.41M |
|
29
Syndax Pharmaceuticals
SNDX
$1.76B
| $23.2M | 1% |
1,214,670
-536,672
| -31% | -$8.94M |
|
30
Idexx Laboratories
IDXX
$46.5B
| $22.3M | 0.96% |
35,800
+5,900
| +20% | +$3.96M |
|
|
LGV
31
DELISTED
Longview Acquisition Corp. II
LGV
| $21.1M | 0.91% |
2,135,900
| – | – |
|
32
Halozyme
HALO
$10.2B
| $20.1M | 0.87% |
493,502
-155,550
| -24% | -$6.5M |
|
33
CALL
Incyte
INCY
$24B
| $18.4M | 0.79% |
267,000
| – | – |
|
34
Zoetis
ZTS
$32.4B
| $16.1M | 0.7% |
83,060
-146,110
| -64% | -$29.5M |
|
|
AFMD
35
DELISTED
Affimed
AFMD
| $15.8M | 0.68% |
255,591
+13,295
| +5% | +$875K |
|
36
Cytokinetics
CYTK
$11B
| $15.5M | 0.67% |
434,500
-314,810
| -42% | -$9.27M |
|
|
37
CVS Health
CVS
$123B
| $14.7M | 0.64% |
173,800
-1,093,530
| -86% | -$91.6M |
|
|
DCPH
38
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $13.1M | 0.57% |
386,190
| – | – |
|
|
RACB
39
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $13M | 0.56% |
1,324,800
| – | – |
|
40
Maravai LifeSciences
MRVI
$922M
| $12.3M | 0.53% |
250,000
-1,005,597
| -80% | -$49.1M |
|
|
BHVN
41
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $11.4M | 0.49% |
82,183
+71,183
| +647% | +$8.89M |
|
42
Encompass Health
EHC
$12.4B
| $8.97M | 0.39% |
150,337
-1,176,195
| -89% | -$74M |
|
43
Fate Therapeutics
FATE
$290M
| $7.61M | 0.33% |
+128,450
| New | +$10.1M |
|
|
MSAC
44
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $7.25M | 0.31% |
744,000
| – | – |
|
45
BioNTech
BNTX
$22.9B
| $6.47M | 0.28% |
+23,690
| New | +$7.53M |
|
|
RAPT
46
DELISTED
RAPT Therapeutics
RAPT
| $5.74M | 0.25% |
23,088
-1,912
| -8% | -$505K |
|
|
OHPA
47
DELISTED
Orion Acquisition Corp. Class A common stock
OHPA
| $5.31M | 0.23% |
547,385
-213
| -0% | -$2.08K |
|
|
48
Incyte
INCY
$24B
| $5.16M | 0.22% |
+75,000
| New | +$5.7M |
|
|
ARYE
49
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $4.94M | 0.21% |
+500,000
| New | +$4.97M |
|
|
CYPH
50
Cypherpunk Technologies Inc
CYPH
$71.7M
| $4.81M | 0.21% |
+120,000
| New | +$2.26M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2021 Portfolio in Review
As of Q3 2021, HealthCor Management held 92 positions worth $2.32B, down 7.4% from $2.5B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
HealthCor Management withdrew a net $103M in Q3 2021, closing 19 positions and reducing 16 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $106M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Consumer Discretionary and Real Estate.
Against the trend, HealthCor Management opened a new position in Jazz Pharmaceuticals worth $60M.
- HealthCor Management's largest Q3 2021 buy was Jazz Pharmaceuticals: 460,790 shares worth $60M.
- HealthCor Management added most to Bristol-Myers Squibb in Q3 2021, an estimated $139M increase.
- HealthCor Management's biggest Q3 2021 reduction was CVS Health, cutting an estimated $91.6M.
- HealthCor Management fully exited Regeneron Pharmaceuticals in Q3 2021, selling an estimated $106M.
- HealthCor Management's ten largest holdings make up 49% of its $2.32B portfolio in Q3 2021.
- HealthCor Management opened 20 new positions and closed 19 in Q3 2021.
- HealthCor Management's portfolio value fell 7.4% quarter-over-quarter to $2.32B.
Based on HealthCor Management's 13F filing for Q3 2021, filed 15 Nov 2021.